{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-041271","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2023-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.983845+00:00","generated_at":"2026-06-07T14:16:36.804615+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"C4 Therapeutics enters license and collaboration agreement with Merck to develop degrader-antibody conjugates","bullets":["C4T grants Merck worldwide exclusive license for DACs directed to an initial undisclosed oncology target.","Merck pays $10 million upfront; C4T eligible for up to ~$600 million in milestones for initial target plus tiered royalties.","Merck has options for three additional targets; if all exercised, total potential payments to C4T up to ~$2.5 billion.","Collaboration leverages C4T's TORPEDO platform for degrader payloads and Merck's antibody conjugation expertise.","Merck responsible for all development, regulatory, manufacturing, and commercialization costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-041271","json":"https://secwatch.observer/filing/0001628280-23-041271.json","markdown":"https://secwatch.observer/filing/0001628280-23-041271.md","text":"https://secwatch.observer/filing/0001628280-23-041271.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023041271/0001628280-23-041271-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023041271/cccc-20231212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:16:36.804615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"976df176eb0ee12dde99497b5d7179632476e3cd","claim":"C4 Therapeutics, Inc. entered into License Agreement with Merck Sharp & Dohme LLC valued at up to approximately $2.5 billion in potential payments across the entire collaboration (effective 2023-12-11).","evidence_excerpt":"C4 Therapeutics, Inc. (“ C4T ”) entered into a License and Collaboration Agreement (“ License Agreement ”) with Merck Sharp & Dohme LLC (“ Merck ”) to collaborate on the development and commercialization of degrader-antibody conjugates ( “ DACs ”: ), an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1662579/000162828023041271/0001628280-23-041271-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Merck Sharp & Dohme LLC"},{"label":"Value","value":"up to approximately $2.5 billion in potential payments across the entire collaboration"},{"label":"Effective","value":"2023-12-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}